In an amicus brief, the Commission argues that courts should evaluate monopolization claims based on the effects of a company’s conduct on competition, not on an intention to harm competitors.
Kevin Kinsella
The Trump administration says it will examine whether Germany’s reimbursement practices constitute “persistent underpayment” for new drugs or “burden or restrict US commerce.”
Regulators are intensifying efforts to enforce information-blocking rules with potential penalties as high as $1m, in a move to increase transparency and interoperability in healthcare.
America’s early-stage clinical trials have increasingly moved overseas, raising concerns about the nation’s long-term competitiveness in biomedical innovation.
The state’s new law reflects growing national concern that deals and short-term financial pressures may threaten care quality and provider stability.
Industry association group argues the state’s Prescription Drug Affordability Act imposes unconstitutional “mandates” on PBMs that manage prescription benefits for employer-sponsored health plans.
Regulator says that warnings about the safety and effectiveness of testosterone replacement therapy should be removed from labels.
Federal prosecutors say New York health officials and state contractor misled regulators and public about the state’s $10 billion home care program.